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Abstract 
Neural precursor/stem cell transplantation therapies promote regeneration in neurological injuries 
but current cell delivery methods have drawbacks. These include risks with surgical microinjection 
(e.g. haemorrhage, embolism), and high cell loss with systemic delivery/passage through fine gauge 
needles. Aerosolized cell delivery offers significant benefits including rapid and minimally invasive 
cell delivery, and ease of delivery to end users. To develop this approach, it is necessary to prove 
that (a) aerosolization does not have detrimental effects on transplant cells and (b) suitable media 
can be identified to support cell delivery. To achieve these aims, cells were sprayed using a 
commercial spray device or stored in Hibernate-ATM, a CO2 independent nutrient solution. 
Histological assessments consisted of cell viability analysis, immunocytochemistry and EdU 
labelling. We show that a major neural precursor transplant population – oligodendrocyte precursor 
cells (OPCs) – survive following aerosolized delivery and retain their capacity for proliferation and 
differentiation (key to their repair function). Hibernate-ATM could support OPCs survival without 
specialised maintenance conditions, with no detrimental impact on cell fate. We consider this data 
supports the concept of a novel class of advanced medical spray devices to facilitate transport and 
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Neural cell transplantation therapies are being utilised for several neurological injuries and diseases, 
with proven benefit.[1–5] The potential mechanisms of pro-regenerative actions include replacement 
of lost cells, immunomodulatory effects and expression of therapeutic proteins such as growth 
factors or enzymes for glial scar breakdown, which result in an environment more conducive to 
regeneration.[6–8]  
 
Neural cell therapies (for clinical use or preclinical testing) are usually delivered through fine bore 
stereotactic cannulae directly into the brain/spinal cord parenchyma. Such invasive delivery 
methods have significant drawbacks from a patient safety and cell therapy efficacy perspective. 
Needle or instrument insertion causes mechanical trauma and carries haemorrhage risk,[2,9–12] of 
particular concern for traumatic injuries where injection into injured tissue increases risks of clinical 
complication. Transplant cells can be damaged due to the mechanical pressure required to inject 
cells through a fine bore cannula into densely packed neural tissue;[9,13] studies suggest that less 
than ca 5% of cells survive in-vivo.[14–16] Transplant solutions for in vivo applications contain high 
cell densities. For example, 20 million neural stem cells in 400 µL of HypoThermosol (5 x107 
cells/mL) were injected into the putamen of stroke patients in one recent clinical trial.[17] Cell death 
and clumping in these suspensions means that injecting cells into such injuries does not achieve 
homogenous cell delivery. Insertion of multiple injection cannulae into the neural parenchyma 
carries a risk of introducing pathogens when instruments are inserted from the external environment 
through neural tissues, which in clinically vulnerable patients, could lead to adverse outcomes. 
Alternative methods for cell delivery include vascular administration such as intravenous or intra-
arterial delivery. However, few cells reach target tissues due to systemic clearance by organs such 
as the lungs and spleen and the risk of embolism is significant.[18–23] Given these barriers to clinical 
translation, there is a need to develop efficacious transplant delivery strategies to support 
administration of neural cell therapy in complex and serious injuries. 
 
Aerosolized delivery of neural transplant cells could potentially provide a novel and realistic 
solution to this translational challenge. It can be envisaged that transplant populations could be 
transported to the end user in a sterile format that allows for cell spray delivery. This approach to 
provision of cells is rapid, does not require specialised stereotactic equipment and is compatible 
with early surgical procedures exposing neural tissue. The minimally invasive nature of spraying 
from a short distance onto neural tissue has no predictable clinical complications. For traumatic 
neural injuries, cells could be delivered with homogenous distribution over areas of extensive 
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as no instrumentation would come into direct contact with the patient during spray delivery unlike 
current other methods of injection. The potential advantages of a neural cell spray are summarised 
in Figure 1. 
 
Figure. 1. Advantages of a neural cell spray for transplantation of neural cell therapies. Image created using 
Biorender.com. 
 
Cell spray technology has been used in a limited number of non-neurological clinical therapies. 
ReCell® technology is an alternative to skin grafts for partial thickness burn wounds where a 
patient skin biopsy is used to generate a mixture of keratinocytes, melanocytes and fibroblasts 
which is spray delivered onto the burn site.[24] An airbrush spray has also been adapted to deliver 
chondrocytes leading to cartilage repair for osteoarthritic knees.[25] A single study assessed an intra-
nasal mesenchymal stem cell delivery approach as an inexpensive and non-invasive cell delivery 
technique to circumvent the blood brain barrier. When tested in a rodent model of Parkinson’s 
disease, an improvement in motor function was reported.[26] To the best of our knowledge, however, 
a spray delivery strategy has never been tested for the direct delivery of neural transplant cells to 
sites of traumatic injuries.  
 
Critical to the success of such a delivery approach, including to end users, would be the 
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achieved without the use of specialised maintenance or transport conditions, such as cold chain 
delivery, which can add substantially to logistical complexity and cost.  
 
To address these issues, this study has used the major neural transplant population of 
oligodendrocyte progenitor cells (OPCs) to establish whether: (i) OPCs can survive aerosolization 
without detriment to key regenerative properties of the cells; and (ii) a widely used tissue transport 
medium (Hibernate-ATM) can support OPC maintenance/survival and subsequent cell recovery 
without the requirement for specialised growth conditions. OPCs are a highly promising transplant 
population for neuro-regeneration having been utilised in clinical trials for acute spinal cord injury 
(SCI) and multiple sclerosis.[27,28] We present data to support the concept that transport and spray 
delivery of neural transplant cells for neurological applications is feasible.  
 
Results  
OPCs retained high cell viability post-spraying  
Immediately following spraying, light microscopy examination revealed even coverage of plate 
surfaces by OPCs. Viable OPCs were observed 48 hours post-spraying, with large numbers of 
viable cells observed in control and experimental conditions and displaying similar morphological 
profiles between conditions (Figure 2a-b). Quantification revealed OPC viability at 48 hours 
following spray delivery was reduced (58.6 ± 11.7%) compared to controls (84.5 ± 2.2%; Figure 
2c). In contrast, following differentiation after spraying, the viability of the spray delivered cells 
(70.8 ± 15.1%) did not significantly differ from controls (76.9 ± 19.6%; Figure 2d-f).  
Figure 2. OPCs show high viability following spray delivery. Live cells were stained with calcein (green arrow), dead 
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triple merged fluorescent images at 48 hours showing control and spray delivered OPCs respectively. (c) Scatter graph 
displaying cell viability 48 hours post-spray delivery. A reduction in spray cell viability compared to the controls was 
observed (**p-value=0.0022, Mann-Whitney test, n=6). (d-e) Representative, triple merged fluorescent images of 
control and sprayed cells at 10 days respectively. Scale bar = 50µm in all images. (f) Scatter graph demonstrating 
viability of control and sprayed cells at 7-10 days. No significant difference was detected between control and spray 
populations (p-value=0.8857, Mann-Whitney test, n=4).  
 
Spray delivered cells retained cell specific marker expression and proliferative capabilities 
At 48 hours, NG2 staining revealed OPCs with typical bipolar and multipolar morphology in both 
control and spray conditions, with no obvious differences in cell morphologies between conditions 
(Figure 3a-b). The proportions of cells expressing NG2 at 48 hours (Fig. 3a-c) did not differ 
significantly between spray delivered cells (78.2 ± 13.2%) and controls (89.4 ± 8.3%). OPCs also 
continued to proliferate following spray delivery and the proportions of proliferating OPCs 
(labelled with EdU over a 24 h period) post-spray (37.6 ± 18.4%) did not statistically differ from 





















Figure 3. Sprayed OPCs express NG2 and retain their ability to proliferate. (a-b) Representative triple-merged 
fluorescence images of OPCs showing NG2 (green) and EdU staining (red) and cell nuclei stained with Hoechst dye 
(blue) 48 hours after control and spray delivery respectively. Scale bars = 50µm. Scatter graph (c) illustrates the 
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value=0.240, Mann-Whitney test, n=6). Scatter graph (d) shows the proportions of proliferating OPCs in control and 
sprayed cells at 48 hours with no significant difference detected (p-value=1.0000, Mann-Whitney test, n=3). 
 
OPCs retained their differentiation capacity following spray delivery 
OPCs differentiated for 8 days post spraying showed the range of expected oligodendrocyte lineage 
cell (OLC) morphologies and increased cellular branching with greater developmental age (Figure 
4a). Depending on the stage of maturation, cells were observed to express NG2 or the mature 
oligodendrocyte marker MBP (Figure 4b-e). At this time point, OPCs represented ca 12% of cells, 
with immature phenotypes representing ca 70% and mature phenotypes representing the remainder 
in sprayed populations. For controls, OPCs represented ca 10% of cells, immature phenotypes ca 
60% with mature phenotypes making up the remainder of cells. There was no statistical difference 
in the proportions of mature cells expressing MBP or the proportions of each cell type at different 
















differentiating into oligodendrocytes. Cartoon (a) demonstrates the maturation stages in the oligodendrocyte lineage; 
OPC, pre-oligodendrocyte, immature oligodendrocyte and mature oligodendrocyte. Fluorescent images (b-e) illustrate 
the different stages of maturation following spray delivery of OPCs where scale bar = 10µm. Representative images (f) 
and (g) show day 10 differentiated OLCs control and spray delivered respectively with scale bars = 50µm. Scatter 
graph (h) shows the proportion of MBP expressing control and spray cells at 10 days with no difference noted 
(p=0.200, Mann-Whitney test, n=3). Graph (i) shows the relative proportions of oligodendrocyte lineage cell 
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oligodendrocyte lineage morphology between the spray and control tested by individual Mann-Whitney tests (p-
values>0.05, n=3). 
 
OPCs retained a high viability following RT (room temperature) or 4oC storage in Hibernate-ATM 
Viable OPCs were observed following 72 hours of storage at control, RT and 4oC conditions 
(Figure 5a-c). Quantification revealed that OPC viability remained high following 72 hours of 
storage in Hibernate-ATM at RT (76.26% ± 6.92) and 4oC (83.34% ± 3.71) and was similar to 
controls (76.18% ± 8.47; Figure 5d). Cells stored at the lower temperatures exhibited rounded 
morphologies (Figure 5a-c). However, following return to 37oC and differentiation for 10 days, 
viable differentiated cells were clearly observed. These showed the branched/multipolar phenotypes 
characteristic of OPCs/immature oligodendrocytes with no obvious differences between 
experimental and control conditions (Figure 5e-g).  
 
 
Figure 5. OPC viability and differentiation after storage in Hibernate-ATM. Live cells were stained with calcein (green 
arrow), dead cells with EH (red arrow) and cell nuclei stained blue with Hoechst dye. (a-c) Representative, tripe-
merged fluorescent images showing OPCs following 72-hour storage in a) control, b) RT Hibernate-ATM and c) 4oC 
Hibernate-ATM conditions. (d) Scatter graph displaying percentage viabilities of OPCs at 3 days with no significant 
differences between conditions (p>0.05, Kruskal-Wallis test, n=4). (e-g) Triple-merged fluorescent images showing 
viable and mature OLC morphologies after differentiation for 7 days following 72 hours storage in e) control 
conditions, f) RT Hibernate-ATM and g) 4oC Hibernate-ATM respectively. All scale bars = 50µm. 
 
OPCs retained specific cellular markers, proliferation and differentiation capabilities following 
storage at RT or 4oC in Hibernate-ATM 
Following recovery from lower temperature storage and then 24 hours culture in OPC maintenance 
medium at 37oC, there was no obvious differences in cellular morphology between the control and 
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significantly differ between OPCs controls (84.33% ± 9.01), storage at RT (78.02% ± 9.71) or 4oC 
(85.51% ± 8.32; Figure 6a-d). OPCs continued to divide during the 24-hour period of cell culturing 
immediately following removal from lower temperature storage, with cells in all experimental 
conditions showing positive EdU staining. There was no significant difference between the 
proportion of dividing OPCs in the controls (25.47% ± 5.72), following storage at RT (12.87% ± 
5.49) or 4oC (27.92% ± 3.86; Figure 6 a-c, i). 
 
OPCs removed from lower temperature storage and differentiated for 7 days showed the range of 
expected OLC morphologies whilst expressing early (NG2) or late (MBP) surface markers 
depending on developmental age (Figure 6e-g). No difference in the expression of MBP was seen 
following differentiation in the controls (46.19% ± 7.79) compared to cells previously stored at RT 
(46.96% ± 3.95) or 4oC (46.54% ± 8.62; Figure 6e-h). Quantification at this timepoint also revealed 
no differences between the proportions for each cell type at different stages in the lineage across the 
control and experimental conditions (Figure 6e-g, j). Immature phenotypes constituted the majority 
of total OLCs contributing over ca 60% in populations previously stored at low temperatures and 
the control. Mature phenotypes accounted for the second most abundant lineage stage and OPCs 
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Figure 6. OPCs retain key cellular characteristics following lower temperature storage in Hibernate-ATM. OPCs are 
stained for NG2 (green top images, red bottom images), oligodendrocytes for MBP (green), proliferating cells with 
EdU (red) and cell nuclei with hoechst (blue). (a-c) Representative, triple-merged fluorescent images showing OPCs 
cultured for 24 hours following 72h storage in (a) control conditions, (b) Hibernate-ATM at RT and (c) Hibernate-ATM at 
4oC. (d) Scatter graph displaying the proportion of NG2 positive cells with no significant differences between cells at 
RT, 4oC and the control (p-value>0.05, Kruskal-Wallis test, n=4). (e-g) Representative, triple-merged fluorescent 
images showing OLCs differentiated after storage in e) control conditions, f) RT Hibernate-ATM and g) 4oC Hibernate-
ATM respectively. All scale bars = 50µm. (h) Scatter graph showing proportions of MBP expressing cells in day 10 
OLCs controls and cells previously stored at RT and 4oC with no significant differences detected (p=0.865, Kruskal-
Wallis test, n=3). (i) Scatter graph displaying proportions of proliferating cells following storage in Hibernate-ATM with 
EdU application over a 24 hour period with no significant differences detected (p-value=0.067, Kruskal-Wallis test, 
n=3). Scatter graph (j) shows quantification for the proportion of different OLC morphologies in each experimental 
condition following differentiation post-recovery at day 10. There were no significant differences between the control 
and cells previously stored at RT and 4oC for all phenotypes of OLCs (p>0.05, Kruskal-Wallis test, n=3). 
 
Discussion 
To our knowledge, this is the first ‘proof-of-concept’ that a cell spray/aerosolized delivery format is 
feasible for cell therapy using the major neural transplant population of OPCs. Second, we show 
that Hibernate-ATM, a CO2 independent nutrient medium approved for human use can support OPC 
survival at low temperatures, without the need for specialised storage conditions. Cells retained 
viability and characteristics essential to their therapeutic potential post-storage, whilst exhibiting 
healthy morphologies and cell marker expression. Taken together, we consider these dual lines of 
evidence provide a strong case for the development of a novel class of advanced spray devices to 
facilitate remote delivery of OPC transplant populations in neural cell therapy.  
 
Numerous studies indicate that OPC transplantation can improve functional outcomes in pre-
clinical models of SCI and traumatic brain injury (TBI).[6,7,21,29] We demonstrate that post-spraying, 
cells retained high viability, proliferative and differentiation capabilities with healthy morphologies 
and cell marker expression. Our data firstly therefore indicate that aerosolization per se, does not 
exert detrimental effects on neural cell populations. Recent clinical trials adopted intra-parenchymal 
cell delivery routes, however, no stereotactic FDA approved injection cannula exists for cell 
transplantation and custom designed cannulae are adopted in clinical trials.[2–4,9] In addition to the 
reduced viability on cell passage through fine bore needles, the potential for blockages within 
cannulae increase the complexity of such approaches in clinical practice. Increased pressures 
required for injection through a blocked cannulae may further damage transplant populations. The 
alternative would be to use a different cannula carrying the risk of a separate insertion path and 
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neurological injuries such as SCI and TBI, where the areas of pathology may be extensive or in a 
relatively superficial anatomical area. For penetration into deeper tissues, the inherent migratory 
abilities of transplanted cells to sites of pathology (‘pathotropism’) could provide a route for cells to 
reach deeper target tissues.  However, this is speculative, and the spray transplantation method may 
not be well suited to delivering cells directly to very specific, localised regions of the CNS such as 
the substantia nigra in Parkinson’s disease. 
 
A reduction in OPC viability was observed post-spraying at the early time but not later following 
cell differentiation. Physical parameters such as droplet size and viscosity, spray velocity, nozzle 
bore size and design can all impact cell viability.[30,31] The initial reduction may be due to the 
inexpensive, commercially available spray device used in this study (with limited potential to 
modify delivery parameters). This spray device is pump operated and therefore a degree of user 
dependence also exists meaning there is likely to be variability in each pump pressure and 
outcomes. Developing bespoke, tuneable spray devices will likely be required to achieve optimal 
cell spray delivery (for example, increasing droplet size to increase cushioning on impact; using 
lower droplet viscosity and increasing nozzle bore diameter Dijkstra et al).[31] Shear force damage 
can also be limited during spraying by cell shrinkage, for example using hyperosmolar sugar 
solutions as demonstrated for macrophages sprayed into the respiratory tract,[32] but neural cell 
viability would need assessment. Additionally, our experiments sprayed cells onto hard, glass 
substrates, but delivery into soft CNS tissues with high water content can be predicted to better 
cushion the mechanical impact, increasing resultant cell viability. Although a reduced viability 
following spray delivery exists in the current study (and requires device optimisation), spraying 
could still offer a comparative advantage versus the widely used techniques of intraparenchymal 
injection or systemic delivery which result in far greater magnitude of cell death/loss. A small 
volume of fine bubbles were found concentrated around the circumference of the wells after the 
spray device had been dispensed, however, this dissipated within seconds after the spraying 
process. We do not consider this impacted the viability or the distribution of the cells post-spraying. 
However, we expect that a better spray design potentially with a wider bore nozzle could further 
limit the issue. 
 
In relation to the use of chemical transport media, given the immediacy to administer cell therapy in 
acute neurological injuries, hospitals require a stock of ‘ready to use cells’ but the infrastructure to 
support remote cell delivery does not currently exist, restricting cell therapies to centres attached to 
manufacturing facilities. The feasibility of implementing a stock system would be increased with 
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Hibernate-ATM is safe between 4 and 25oC, potentially providing the capability to transport cells at 
ambient temperatures. Removing the necessity of cold-chain transport is particularly desirable as it 
removes complexity, is inexpensive and compatible with changing environments. The chemical 
composition of Hibernate-ATM can be cross referenced with other cell storage media to expand the 
range of excipients for use in neural cell therapy. While we have shown Hibernate-ATM has 
potential for use as an OPC storage medium, future transport solutions may be combined with gel 
matrices which provide mechanical protection during transit. Such an approach is being developed 
for non-neural transplant transportation where a range of cells have been encapsulated in 
polymers.[33,34] This technology could be integrated into a spray device enabling sterile 
transportation and spraying using a single medical product. Further refinements to develop novel 
neurosurgical devices seem feasible. For example, some neurosurgical products such as dural 
sealants are dual-chamber spray devices where the contents are mixed immediately prior to 
delivery. Multiple cell types, growth factors or pharmaceutical agents such as antimicrobial agents 
could also be tested in such ‘multi-purpose’ sprays. These refinements and future optimisation of a 
neural cell spray device can be achieved through appropriate collaboration with the pharmaceutical 
industry.    
 
If the feasibility of optimising spray delivery devices (with appropriate supportive chemical media) 
is proven successful, then this approach warrants investigation for cell delivery in locations remote 
from cell manufacturing facilities. Neural cell therapy development has prioritised chronic 
neurological conditions such as degenerative pathologies, where cell therapy timings can be 
planned in advance. By contrast, conditions such as TBI have a limited time window post-injury for 
cell therapies to be effective with most pre-clinical trials adopting early administration with a view 
to suppressing the initial immune response.[6] This would present logistical challenges in existing 
healthcare structures. Patients require stabilisation and prevention of secondary injuries, due to the 
frequent multiple organ injuries associated with major trauma conditions, before transferring to 
facilities offering manufacture and delivery of cell therapies. This obstacle is especially 
pronounced in the military context with a high TBI incidence,[35] where patient evacuation may take 
days to weeks.[36] Further development of the spray device strategy therefore appears warranted for 
OPCs and other neural transplant populations. This can be predicted to be of high clinical benefit in 
the surgical management of serious neurological injuries overcoming translational barriers 
associated with current cell delivery routes. Delivery of neural cells in a spray format to remote 
locations has added potential for increasing collaboration between laboratories and resource poor 
environments, benefiting scientific and clinical scientific communities with limited access to cell 
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Conclusions 
Aerosolised delivery of neural transplant populations is feasible. Storage of cells in a CO2 
independent nutrient medium is also feasible, with important regenerative properties being retained 
by the ‘stored’ cells post-recovery. Together, these lines of evidence support the development of a 
novel class of medical devices based on spray delivery and transport in suitable supportive 




All cell culture reagents and cell culture grade plastics were from Thermo Fisher Scientific 
(Loughborough, UK) or Sigma-Aldrich (Dorset, UK) unless otherwise stated. For media 
components, items purchased elsewhere were fetal bovine serum from Biosera (Sussex, UK, catalog 
no. 11573397) and human recombinant basic Fibroblast Growth Factor (FGF-2, catalog no. 100-
18B) and platelet derived growth factor AA (PDGF-AA, catalog no. 100-13A) from Peprotech 
(London, UK). For assays calcein was from VWR (Pennsylvania, USA, catalog no. 89139-470), 
normal donkey serum (NDS, catalog no. 017-000-121) was from Stratech Scientific 
(Cambridgeshire, UK) and mounting medium with 4’6-diamiodino-2-phenylindole (DAPI, catalog 
no. H-1000) was from Vectashield (Peterborough, UK). Primary antibodies were anti-MBP from 
Bio-Rad (California, USA, catalog no. aa82-87) and anti-NG2 from Dako Omnis (USA, catalog no. 
AB5320). Secondary antibodies for both fluorescein isothiocyanate (FITC) and cyanine 3 (Cy3) 
included donkey anti-rabbit (catalog no. GTX26701-GTX) and donkey anti-rat (catalog no. LS-
C351180-LSP) from Stratech Scientific (Cambridgeshire, UK). Mist plastic pump spray bottles 
(10ml) were utilised as spray devices and sourced from SelfTek (UK). All animal use was in 
accordance with the Animals (Scientific Procedures) Act of 1985 (UK). Hibernate-ATM was 
purchased from Thermo Fisher Scientific (UK). 
 
Preparation of primary mixed glial cultures (MGCs) 
MGCs were derived from cortices of postnatal day one to three CD1 mice and propagated until 
stratification into a bed layer of astrocytes with loosely adherent OPCs and microglia as previously 
described.[37] Cells were cultured for 10 days in D10 medium comprising of DMEM supplemented 
with sodium pyruvate (100 mM), GlutaMAX-I (1 mM), penicillin (5000 U/ml), streptomycin (5000 
µg/ml) and 10% FBS with a 50% medium change every 2-3 days. Specific neural cell types can be 
isolated from these cultures through sequential shaking (all at 220 rpm) and subsequent enzymatic 
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and removing the medium. Fresh medium was added and the cultures placed on the orbital shaker 
for 16-18 hours during which time OPCs detach and can be collected. This method has been 
previously described to derive a high purity of OPCs (>85%).[38] 
 
Evaluating spray delivery of cells 
OPCs were suspended at 2.0 x 105 cells/ml in OPC maintenance medium (DMEM, GlutaMAX-1 (2 
mM), sodium pyruvate (1 mM), biotin (10 nM), insulin (5 µg/ml), hydrocortisone (10 nM), sodium 
selenite (30 nM), transferrin (5 µg/ml), penicillin (50 U/ml), streptomycin (50 µg/ml), 0.1% bovine 
serum albumin, PDGF-AA (10 ng/ml), FGF-2 (10 ng/ml)). Cell solutions were then sprayed or 
pipetted (control) onto nitric acid treated poly-D-lysine coated coverslips. For controls, 360 µL of 
cell solution was pipetted into each well. For spray delivered cells, three sprays were delivered to 
each well (calculated to deliver 360 µL in total) from a distance of approximately one centimetre. 
Before each discharge, the spray device was gently inverted to ensure an even cell suspension 
distribution throughout the canister. OPCs were cultured for 48 hours in OPC maintenance medium 
before a subset of wells was switched to OPC differentiation medium (DMEM, GlutaMAX-I (2 
mM), sodium pyruvate (1 mM), 1% N2 supplement, penicillin (50 U/ml), streptomycin (50 µg/ml), 
triiodothyronine (30 nM), thyroxine (30 nM)) for 5-8 days. OPCs underwent 50% medium changes 
every 2-3 days. 
 
Evaluating storage of cells in Hibernate-ATM 
OPCs were suspended at a density of 2.0x105 cells/mL in Hibernate-ATM, pre-warmed to RT, and 
300 μL of this suspension was added onto nitric acid treated PDL coated coverslips in each well of 
a 24 well plate. Different well plates were sealed with parafilm and stored undisturbed at 4oC or RT 
(21 to 25 oC) for 72 hours. The same cell density and volume per well was used for controls. 
However, here OPC maintenance medium was employed. Control samples were stored at 37oC, 5% 
CO2 with no medium changes for 72 hours. Upon removal from lower temperature storage or 
control conditions, cells were immediately warmed or maintained at 37oC. A subset of wells were 
used for analyses of viability and proliferation of OPCs and a subset of wells were switched to OPC 
differentiation medium for 7 days. OPCs in differentiation medium then underwent 50% medium 
changes every 2-3 days. Conditions of RT and 4oC were selected for cell storage as are desirable 
transportation temperatures. RT transportation does not require any specialised refrigerated cold 
chain transport equipment associated with the costs of purchase, installation, running and 
maintenance. Transportation at 4oC represents a more standard format and likely to be available due 
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Characterisation of cell cultures  
Cell viability was assessed using a live-dead assay where of cell specific culturing media (300 μL) 
with calcein (4 μM), Hoechst (1 mg/ml) and EH (6 μM) was added to each well for 30 minutes 
before imaging. Proliferation assays were performed using a Click-iT EdU imaging kit according to 
the manufacturer’s instructions where OPCs were incubated with component-A for 24 hours before 
fixation. For experiments of cells in Hibernate-ATM, both live-dead and Click-iT EdU assays were 
initiated immediately following removal from low temperature storage.  
 
Immunocytochemistry was performed to identify cell specific markers and assess cell 
morphologies. Samples were fixed in 4% PFA for 20 minutes at RT. Cells were then washed in 
PBS three times before addition of blocking solution (5% NDS in PBS-0.3% Triton X-100) for 30 
minutes. Primary antibodies diluted in blocking solution were added to samples and incubated 
overnight. These were NG2 (1:150) to detect OPCs and MBP (1:200) to detect oligodendrocytes. 
Primary antibodies were then removed, samples washed three times with PBS and incubated for 30 
minutes in blocking solution. Appropriate secondary antibodies diluted in blocking solution (1:200) 
were added for two hours before three PBS washes. Samples were mounted onto glass slides using 
mounting medium with DAPI and left for 30 minutes before imaging.  
Antibody Dilution 
Anti-MBP (rat) 1/200 
Anti-NG2 (rabbit) 1/150 
Anti-rat 1/200 
Anti-rabbit 1/200 
Table 1. Antibodies and dilution factors. 
 
Image acquisition and quantification  
Fluorescence micrographs were obtained on a Zeiss Axio Observer Z1 equipped with an AxioCam 
MRm camera powered by Zen 2 software. For each assay, five fields were selected from the middle 
and four corners of the coverslip. ImageJ software was utilised for quantification. For each assay, 
total cell nuclei were counted per field. Viability assay analysis consisted of counting live cells 
positive for calcein (green) and dead cells positive for EH (red) and expressing these as a proportion 
of total cell nuclei. Live dead assays report a current viability of a culture where following cell 
death, cells begin to detach and are washed away by media changes and are therefore undetectable 
in subsequent assays. Immunostained images were quantified by counting positively stained nuclei 
and total nuclei per field. Results were expressed as the total number of cells positive for a specific 
marker as a proportion of the total number of cells. Dividing OPCs where quantified by counting 
cells positive for both EdU (red) and NG2 (green) and expressing these as a proportion of total 
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four groups namely OPCs (immature, bipolar), pre-oligodendrocytes (two or more processes with 
secondary and tertiary branching), immature oligodendrocytes (multiple processes with extensive 
secondary and tertiary branching), or mature oligodendrocytes (extensive membrane elaboration 
with ‘spider-web’ morphologies).[39] Morphological categories were expressed as the total number 
of cells exhibiting a morphology as a proportion of the total number of OLCs.  
 
Statistical analysis 
GraphPad Prism 9.0.0 software was utilised for all statistical analyses. Data was analysed using 
non-parametric Mann-Whitney or Kruskal-Wallis tests. All results are expressed as the mean ± 
standard error of the mean. In results, ‘n’ refers to the number of primary cultures used per 
experiment, each derived from a separate litter of animals.  
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